Clinical Trial

Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-01-31; most recent amendment 2024-12-27.
Trial Details
NCT Number NCT05709249
Lead Sponsor Jiangsu Famous Medical Technology Co., Ltd.
Collaborators: Jiangsu Province Hospital of Traditional Chinese Medicine, Ministry of Science and Technology of the People´s Republic of China
Conditions Colon Cancer
Enrollment 730 participants
Start Date 2022-12-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-30